Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Methylphenidate extended release - Highland Therapeutics

Next Previous
Drug Profile

Methylphenidate extended release - Highland Therapeutics

Alternative Names: Benjorna; HLD-200; JORNAY PM; Methylphenidate delayed release; Methylphenidate hydrochloride extended release

Latest Information Update: 26 Nov 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Highland Therapeutics
  • Developer Highland Therapeutics; Ironshore Pharmaceutical and Development
  • Class Behavioural disorder therapies; Neuroprotectants; Nootropics; Phenylacetates; Piperidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Central nervous system stimulants; Dopamine uptake inhibitors; Monoamine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder

Most Recent Events

  • 11 Jun 2019 Launched for Attention-deficit hyperactivity disorder (In children, In adolescents) in USA (PO)
  • 18 May 2019 Adverse events data from a phase III trial in Attention Deficit Hyperactivity Disorder presented at the 172nd Annual Meeting of the American Psychiatric Association (APA-2019)
  • 09 Aug 2018 Ironshore Pharmaceuticals intends to launch methylphenidate modified release in first half of 2019
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top